Multimodal Data Fusion
Integrates clinical trial data, molecular profiles, biomarker signals, and patient stratification variables for a unified view of therapeutic performance.
About Our Platform
Reviving Assets from Clinical Trial Setbacks
Each year, pharmaceutical companies face substantial losses from assets that fail in pivotal trials. DrugReboot.Ai™ is ThinkBio.Ai®’s advanced platform designed to systematically analyze the root causes of clinical failure and identify alternative development paths. By combining proprietary data with AI-driven insights, it enables informed decision-making to recover and repurpose promising molecules.
Why Use DrugReboot.Ai™?
From Sunk Costs to Strategic Recovery
DrugReboot.Ai™ performs root cause analysis to propose alternative strategies:
- Repurposing in a New Indication – Identifying alternative disease areas with stronger therapeutic potential
- Population Stratification – Pinpointing responsive patient cohorts
- Combination Therapy Design – Suggesting combinations with other targets to achieve superior therapeutic index.
How it works
Integrated AI Framework for Rational Repositioning
DrugReboot.Ai™ combines multimodal data, knowledge graphs and domain-specific foundation models to discover molecular features associated with drug response. It combines the molecular features with the patient’s clinical attributes to predict the reasons why the drug failed in the clinical trial. Additional analysis using disease models identifies strategies for salvaging the therapy. Delivered via secure cloud or on-premises deployment, the analysis provides actionable insights and supporting evidence to guide clinical and commercial decisions.
Key Features & Capabilities
Foundation Model-Powered Insights
Applies fine-tuned large language and domain-specific models to uncover root causes of trial failure and generate repositioning hypotheses.
Combination Therapy Discovery
Suggests rational co-therapies based on pathway analysis, drug interaction patterns, and therapeutic synergies
Secure & Flexible Deployment
Available as a secure cloud-based solution or deployable on-premises, ensuring compliance with enterprise data governance.
Biomedical Knowledge Graphs
Leverages structured biomedical relationships to identify novel indications, mechanisms of action, and target-patient alignments
Indication Mapping & Patient Stratification
Identifies viable alternative indications and responsive subpopulations using real-world evidence and biological markers
Actionable Repositioning Reports
Delivers expert-validated recommendations with supporting evidence, visualizations, and traceable rationale to accelerate decision-making
Frequently Asked Questions
DrugReboot.Ai™ combines multimodal data, biomedical knowledge graphs, and AI-driven models to analyze why a therapy failed and identify potential strategies to revive its development through new indications, responsive patient populations, or optimized treatment combinations.
Yes. DrugReboot.Ai™ analyzes biological, molecular, and clinical data to uncover alternative disease indications where existing assets may demonstrate stronger therapeutic potential.
DrugReboot.Ai™ uses AI-powered foundation models, biomedical knowledge graphs, and multimodal data analysis to identify hidden relationships between molecules, diseases, biomarkers, and patient populations, generating evidence-supported repositioning strategies.
DrugReboot.Ai™ identifies patient subgroups that may be more likely to respond to a therapy by analyzing biomarkers, molecular characteristics, and clinical attributes, helping optimize future clinical development strategies.
DrugReboot.Ai™ helps organizations make data-driven pipeline decisions by uncovering reasons behind trial failures, accelerating asset recovery, and identifying new therapeutic opportunities to maximize pipeline value and return on investment.
DrugReboot.Ai™ integrates clinical trial data, molecular profiles, biomarkers, patient characteristics, and biomedical knowledge to analyze potential causes of therapeutic failure. By combining AI-driven insights with disease models, the platform uncovers hidden response patterns and identifies evidence-based strategies to reposition or optimize failed assets.
Build the future of
biology with us
Contact Us
Stay Ahead with
ThinkBio.Ai®
Subscribe to our newsletter to receive the latest updates on products, sustainability efforts and services.